By Michael Susin

 

AstraZeneca PLC and Merck & Co. said Thursday that Lynparza, its olaparib drug maintenance treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, has been approved in China.

The Anglo-Swedish pharmaceutical giant said the approval by China's National Medical Products Administration was based on a positive analysis of its Phase III trial, which showed that Lynparza plus bevacizumab strongly improved progression-free survival against bevacizumab treatment on its own for patients with HRD-positive advanced ovarian cancer.

The company said the treatment will be used in patients who are in complete or partial response to the first-line platinum-based chemotherapy.

The initial results from the late-study trials showed that the treatment reduced the risk of disease progression or death by 67%.

The treatment collaboration between AstraZeneca and Merck & Co., known as MSD outside the U.S. and Canada, is approved in the U.S. and several other countries under the same conditions and is currently under regulatory review in other countries around the world.

In China, Lynparza is also approved for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer, it added.

 

Write to Michael Susin at michael.susin@wsj.com

 

(END) Dow Jones Newswires

September 22, 2022 02:54 ET (06:54 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 10 2022 まで 11 2022 Astrazenecaのチャートをもっと見るにはこちらをクリック
Astrazeneca (LSE:AZN)
過去 株価チャート
から 11 2021 まで 11 2022 Astrazenecaのチャートをもっと見るにはこちらをクリック